Related Experiment Video
Updated: Jan 8, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Alizée Lebeau1,2, Athanasios Kakkos2, Natacha Leroi3
1Department of Medical Oncology, CHU of Liège, Liège, Belgium.
Abstract:
Synthetic lethality (SL) is a promising therapeutic concept that relies on the indirect targeting of vulnerabilities acquired through genetic mutations. Ovarian and endometrial cancers frequently exhibit mutations in the breast cancer (BRCA), phosphatase and tensin homolog (PTEN), AT-rich interactive domain-containing protein 1A (ARID1A) and TP53 genes, as well as DNA repair pathway deficiencies. Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated remarkable efficacy in various cancers with BRCA mutations and homologous recombination deficiency. In addition to PARPi, there has been an expansion of drugs exploiting the selective vulnerability of cancer cells via SL, such as WEE1 kinase and Ataxia Telangiectasia and Rad3-related protein (ATR). WEE1 inhibitors have shown encouraging results in combination with chemotherapy, increasing the objective response rate in patients with platinum-resistant TP53-mutated ovarian cancer. ATR inhibitors are currently being evaluated in ARID1A-mutated tumours, with preliminary results confirming their therapeutic potential.
Insights
Synthetic lethality offers a novel approach to cancer therapy by targeting genetic mutations. New drugs like WEE1 and ATR inhibitors show promise for ovarian and endometrial cancers with specific genetic alterations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Synthetic lethality (SL) targets cancer vulnerabilities arising from genetic mutations.
- Ovarian and endometrial cancers often have mutations in BRCA, PTEN, ARID1A, and TP53, alongside DNA repair deficiencies.
Purpose of the Study:
- To explore the therapeutic potential of synthetic lethality strategies in ovarian and endometrial cancers.
- To review the efficacy of emerging drugs targeting specific genetic vulnerabilities.
Main Methods:
- Review of current literature on synthetic lethality drug development.
- Analysis of clinical trial data for PARP, WEE1, and ATR inhibitors in relevant cancer types.
Main Results:
- Poly(ADP-ribose) polymerase inhibitors (PARPis) are effective in BRCA-mutated and homologous recombination-deficient cancers.
- WEE1 inhibitors show promise in combination therapy for TP53-mutated, platinum-resistant ovarian cancer.
- ATR inhibitors are under investigation for ARID1A-mutated tumors with positive preliminary outcomes.
Conclusions:
- Synthetic lethality represents a significant advancement in targeted cancer therapy.
- Emerging drugs like WEE1 and ATR inhibitors offer new therapeutic avenues for specific cancer mutations.
- Further research is warranted to optimize combination strategies and expand treatment options.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers